上海莱士：血液制品中的罕见病药物仍适用3%简易征收，其他血液制品业务不再适用3%简易征收

Group 1 - The core issue raised by investors is the potential change in VAT collection method from 3% simplified taxation to 13% general taxation, and its expected impact on tax costs and company profits [1] - Shanghai Laishi responded that rare disease drugs within blood products will still be subject to the 3% simplified taxation, while other blood product businesses will no longer benefit from this rate, indicating a unified industry policy adjustment [1] - The company acknowledged that the adjustment will have a certain impact on the industry, but it plans to mitigate the effects through optimized procurement management and enhanced input tax deduction management [1]